During the past decade, Uniklinik fuer Neurologie, Medizinische Universitaet Innsbruck; Department fuer Neurologie conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 6 clinical trials were completed, i.e. on average, 85.7% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 3 clinical trials were completed. i.e. 60% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Uniklinik fuer Neurologie, Medizinische Universitaet Innsbruck; Department fuer Neurologie" #1 sponsor was "Hoffmann-La Roche" with 7 trials, followed by "Boehringer Ingelheim" with 2 trials sponsored, "Ipsen" with 2 trials sponsored, "Theravance Biopharma" with 2 trials sponsored and "Biogen" with 2 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Uniklinik fuer Neurologie, Medizinische Universitaet Innsbruck; Department fuer Neurologie" #1 collaborator was "Elan Pharmaceuticals" with 1 trials as a collaborator, "Michael J. Fox Foundation for Parkinson's Research" with 1 trials as a collaborator and "Prothena Biosciences Limited" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Uniklinik fuer Neurologie, Medizinische Universitaet Innsbruck; Department fuer Neurologie" are "Cervical Dystonia" (2 trials), "Multiple Sclerosis, Relapsing-Remitting" (2 trials), "Symptomatic Neurogenic Orthostatic Hypotension" (2 trials), "Glioblastoma" (1 trials) and "Huntington Disease" (1 trials). Many other conditions were trialed in "Uniklinik fuer Neurologie, Medizinische Universitaet Innsbruck; Department fuer Neurologie" in a lesser frequency.

Most popular intervention types in "Uniklinik fuer Neurologie, Medizinische Universitaet Innsbruck; Department fuer Neurologie" are "Drug" (15 trials), "Biological" (2 trials), "Other" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "Ocrelizumab" (3 trials), "Botulinum toxin type A" (2 trials), "ampreloxetine" (2 trials) and "1. Tesofensine (NS 2330)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Uniklinik fuer Neurologie, Medizinische Universitaet Innsbruck; Department fuer Neurologie" are 16 trials for "All" genders.

Currently, there are NaN active trials in "Uniklinik fuer Neurologie, Medizinische Universitaet Innsbruck; Department fuer Neurologie". undefined are not yet recruiting, undefined are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in Uniklinik fuer Neurologie, Medizinische Universitaet Innsbruck; Department fuer Neurologie, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Uniklinik fuer Neurologie, Medizinische Universitaet Innsbruck; Department fuer Neurologie, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".